Recursion Pharmaceuticals (RXRX) Gains from Investment Securities (2020 - 2026)

Recursion Pharmaceuticals has reported Gains from Investment Securities for 7 years, with the latest figure at -$1.7 million in Q1 2026.

• For the quarter ending Q1 2026, Gains from Investment Securities rose 65.3% year-over-year to -$1.7 million; the trailing twelve-month figure through Mar 2026 stood at -$6.4 million (up 70.54% YoY), and the FY2025 full-year result was -$9.5 million, up 41.55% from the prior year.
• Gains from Investment Securities for Q1 2026 stood at -$1.7 million, up from -$2.9 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $5.9 million in Q2 2024, with the low at -$17.0 million in Q4 2024.
• Historically, Gains from Investment Securities has averaged -$1.5 million across 5 years, with a median of -$716000.0 in 2023.
• The largest YoY upside for Gains from Investment Securities was 25926.09% in 2024 against a maximum downside of 1233.36% in 2024.
• Recursion Pharmaceuticals' Gains from Investment Securities stood at -$4.8 million in 2022, then jumped by 131.36% to $1.5 million in 2023, then plunged by 1233.36% to -$17.0 million in 2024, then soared by 82.96% to -$2.9 million in 2025, then surged by 42.18% to -$1.7 million in 2026.
• The last three Gains from Investment Securities figures came in at -$1.7 million (Q1 2026), -$2.9 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.